<DOC>
	<DOC>NCT00040053</DOC>
	<brief_summary>The purpose of this study is to assess ondansetron for the treatment of methamphetamine dependence.</brief_summary>
	<brief_title>Ondansetron for the Treatment of Methamphetamine Dependence - 1</brief_title>
	<detailed_description>This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron.</detailed_description>
	<mesh_term>Amphetamine-Related Disorders</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>18 years of age. Treatment seeking for meth dependence. Please contact site director for more details.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>amphetamine dependence</keyword>
</DOC>